Adjuvant Chemotherapy in Patients With Lymph Node Metastasis After Radical Surgery in Cervical Cancer
NCT ID: NCT01487226
Last Updated: 2011-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
69 participants
INTERVENTIONAL
2008-01-31
2015-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To evaluate the 3-year disease free survival Second endpoints
* To evaluate the 3-year \& 5-year overall survival To analyze the toxicity and the quality of life
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
paclitaxel
Paclitaxel 175 mg/m2 over 3 hr Repeat every 3 weeks \* 6 cycles
Cisplatin 50mg/m2
Cisplatin 50mg/m2
Repeat every 3 weeks \* 6 cycles
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* histology; squamous, adeno, adenosquamous subtype
* age; 20∼70 years
* performance status; GOG 0∼2
* no medical illness
* hematologic, renal, hepatic function; normal
* grossly no residual disease
* histologically confirmed lymph nodes metastases
* no parametrial extension and negative resection margin
* number of retrieved lymph nodes; ≥ 20
Exclusion Criteria
* patients with uncontrolled infection
20 Years
70 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Korean Gynecologic Oncology Group
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Taek Sang Lee
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jong Min Lee, MD
Role: PRINCIPAL_INVESTIGATOR
Kyung-Hee University East-West Med. Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
KGOG
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Eunkyung Park
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KGOG1012
Identifier Type: -
Identifier Source: org_study_id